Table 4.
Unadjusted and adjusted models for predictors of mortality across 33 MSF sites providing ART care
| Model outcome | Level | Mortality | Mortality with lost to follow-up as a competing risk | ||
|---|---|---|---|---|---|
| Predictor | Adjusted hazard ratio (95 % CI) | p value | Adjusted hazard ratio (95 % CI) | p value | |
| Treatment interruption | 0.21 (0.18, 0.23) | <0.01 | 0.95 (0.89, 1.02) | 0.18 | |
| WHO stage at ART initiation | 1 | Ref. | Ref. | ||
| 2 | 1.06 (0.81, 1.40) | 0.67 | 1.06 (0.80, 1.40) | 0.68 | |
| 3 | 2.41 (1.95, 2.98) | <0.01 | 2.50 (2.02, 3.09) | <0.01 | |
| 4 | 4.31 (3.48, 5.33) | <0.01 | 4.50 (3.64, 5.56) | <0.01 | |
| CD4 count at ART initiation (cells/μL) | <200 | Ref. | Ref. | ||
| 200–350 | 0.55 (0.48, 0.64) | <0.01 | 0.54 (0.47, 0.62) | <0.01 | |
| >350 | 0.41 (0.30, 0.55) | <0.01 | 0.40 (0.29, 0.53) | <0.01 | |